Institutional members access full text with Ovid®

Share this article on:

Community-acquired bacterial meningitis

Costerus, Joost M.; Brouwer, Matthijs C.; Bijlsma, Merijn W.; van de Beek, Diederik

Current Opinion in Infectious Diseases: February 2017 - Volume 30 - Issue 1 - p 135–141
doi: 10.1097/QCO.0000000000000335
CNS INFECTIONS: Edited by Matthijs C. Brouwer

Purpose of review: Bacterial meningitis is a medical emergency and is associated with a high disease burden. We reviewed recent progress in the management of patients with community-acquired bacterial meningitis.

Recent findings: The worldwide burden of disease of bacterial meningitis remains high, despite the decreasing incidence following introduction of routine vaccination campaigns. Delay in diagnosis and treatment remain major concerns in the management of acute bacterial meningitis. European Society of Clinical Microbiology and Infectious Diseases guidelines strive for a door-to-antibiotic-time less than 1 h. Polymerase chain reaction (PCR) has emerged as an important diagnostic tool to identify the causative organism. Point-of-care tests using fast multiplex PCR have been developed, but additional value has not been proven. Although anecdotal observations advocate pressure-based management, a randomized controlled trial will need to be performed first to determine efficacy and safety of such an aggressive treatment approach. Adjunctive dexamethasone remains the only adjunctive therapy with proven efficacy.

Summary: The incidence of bacterial meningitis has been decreasing after the implementation of effective vaccines. Treatment should be administered as soon as possible and time to treatment should not exceed 1 h.

Department of Neurology, Centre of Infection and Immunity Amsterdam (CINIMA), Academic Medical Centre, Amsterdam, the Netherlands

Correspondence to Prof. Dr. Diederik van de Beek, MD, PhD, Department of Neurology, Centre of Infection and Immunity Amsterdam (CINIMA), Academic Medical Centre, University of Amsterdam, PO Box 22660, 1100DD Amsterdam, the Netherlands. Tel: +31 20 566 3842; fax: +31 20 566 9374; e-mail: d.vandebeek@amc.uva.nl

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.